Porgaviximab

Drug Profile

Porgaviximab

Alternative Names: Anti-Ebola monoclonal antibody - Mapp Pharmaceuticals; ZMapp

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapp Biopharmaceutical; Public Health Agency of Canada
  • Developer Mapp Biopharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Ebola virus infections

Most Recent Events

  • 12 Oct 2016 Safety data from the PREVAIL II phase I/II trial in Ebola virus infections released by Mapp Biopharmaceuticals
  • 23 Feb 2016 Efficacy data from a phase I/II trial in Ebola virus infections released by Leaf Biopharmaceutical
  • 23 Feb 2016 Leaf Biopharmaceutical completes a phase I/II trial in Ebola virus infections in USA, Sierra Leone, Liberia and Guinea (IV) (NCT02363322)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top